DataMeds AI, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On September 11, 2026, DataMeds AI (NASDAQ: MEDS, ~$27.1M market cap) acquired 100% of Helomics Corporation from Axe Compute Inc. (NASDAQ: AGPU) for 636,328 shares of DataMeds common stock (19.99% of DataMeds' pre-transaction outstanding shares, ~$635K at market) plus a $1.363672M convertible note at 7% annual interest, convertible at $1.00/share, maturing September 2029. Helomics is a CLIA/CAP-certified cancer diagnostics lab with precision oncology CRO services. DataMeds received the lab, equipment, business operations, and $1.5M cash; no third-party debt transferred. The transaction closed with Axe Compute retaining a significant equity stake in DataMeds post-close.
Why this rating
Transformational for micro-cap: $1.5M cash inflow + operating cancer diagnostics business materially expands DataMeds' revenue footprint and market addressability (~6% dilution via 19.99% stake issuance is acceptable given asset/cash gain). Seller retains upside; positive strategic fit into DataMeds' healthcare platform.
Price action (we called it positive)
before filing · preread $5.99 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.